Center for Scientific Review; Notice of Closed Meetings, 14023-14024 [2022-05139]
Download as PDF
Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices
NCI Technology Transfer Center by
email (richard.girards@nih.gov) or
phone (240–276–6825).
Intellectual Property
lotter on DSK11XQN23PROD with NOTICES1
E–003–2014: Agents That Specifically
Bind Matrilin-3 and Their Use/Cartilage
Targeting Agents and Their Use
1. United States Provisional Patent
Application No. 61/927,904, filed 15
January 2014 (HHS Reference No. E–
003–2014–0–US–01);
2. United States Patent No.
10,323,083, issued 18 June 2019 (HHS
Reference No. E–003–2014–0–US–06);
3. United States Patent No.
10,954,291, issued 23 March 2021 (HHS
Reference No. E–003–2014–0–US–07);
4. United States Patent Application
No. 17/177,644, filed 17 February 2021
(HHS Reference No. E–003–2014–0–US–
12);
5. International Patent Application
No. PCT/US2015/011433, filed 14
January 2015 (HHS Reference No. E–
003–2014–0–PCT–02);
6. Australia Patent No. 2015206515,
issued 26 March 2020 (HHS Reference
No. E–003–2014–0–AU–03);
7. Canada Patent Application No.
2931005, filed 14 January 2015 (HHS
Reference No. E–003–2014–0–CA–04);
8. European Patent No. 3 094 350 B1,
issued 04 March 2020 (HHS Reference
No. E–003–2014–0–EP–05) and all of its
national validations;
9. European Patent Application No.
19219282.1, filed 14 January 2015 (HHS
Reference No. E–003–2014–0–EP–11);
and
10. any and all other U.S. and ex-U.S.
patents and patent applications
claiming priority to any one of the
foregoing, now or in the future.
The patent and patent application
rights in these inventions have been
assigned and/or exclusively licensed to
the government of the United States of
America.
The prospective exclusive license
territory may be worldwide and the
fields of use may be limited to the
following: The manufacture,
distribution, sale and use of fusion
proteins for the treatment of (a) growth
disorders and (b) diseases of cartilage
degeneration.
These technologies disclose, e.g.,
monoclonal antibodies and antibody
fragments that specifically bind to
matrilin-3, conjugates including these
molecules, and nucleic acid molecules
encoding the antibodies, antigen
binding fragments and conjugates. Also
disclosed are compositions including
the disclosed antibodies, antigen
binding fragments, conjugates, and
nucleic acid molecules. Methods of
VerDate Sep<11>2014
17:10 Mar 10, 2022
Jkt 256001
treating or inhibiting a cartilage disorder
in a subject, as well as methods of
increasing chondrogenesis in cartilage
tissue are further provided. The
methods can be used, for example, for
treating or inhibiting a growth plate
disorder in a subject, such as a skeletal
dysplasia or short stature.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR 404. The
prospective exclusive license will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: March 7, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2022–05140 Filed 3–10–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
14023
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Advancing
Gender Inclusive Excellence (AGIE)—
Coordinating Center U54.
Date: April 8, 2022.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive Bethesda,
MD 20892, (Virtual Meeting).
Contact Person: Shivani Sharma, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, (240) 507–7661,
shivani.sharma@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Initiative Research in Hematology.
Date: April 11, 2022.
Time: 2:00 p.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Larry Pinkus, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4132,
MSC 7802, Bethesda, MD 20892, (301) 435–
1214, pinkusl@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Endocrinology, Metabolism,
Nutrition and Reproductive Sciences.
Date: April 14, 2022.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Baskaran Thyagarajan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 800B,
Bethesda, MD 20892, (301) 867–5309,
thyagarajanb2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Virology.
Date: April 15, 2022.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Kumud Singh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesa, MD 20892, (301) 761–7830,
kumud.singh@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
E:\FR\FM\11MRN1.SGM
11MRN1
14024
Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices
Dated: March 7, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
National Institutes of Health
[FR Doc. 2022–05139 Filed 3–10–22; 8:45 am]
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
In compliance with the
Paperwork Reduction Act of 1995, the
U.S. Coast Guard intends to submit an
Information Collection Request (ICR) to
the Office of Management and Budget
(OMB), Office of Information and
Regulatory Affairs (OIRA), requesting an
extension of its approval for the
following collection of information:
1625–0122, Cargo Securing Manuals;
without change. Our ICR describes the
information we seek to collect from the
public. Before submitting this ICR to
OIRA, the Coast Guard is inviting
comments as described below.
DATES: Comments must reach the Coast
Guard on or before May 10, 2022.
ADDRESSES: You may submit comments
identified by Coast Guard docket
number [USCG–2022–0155] to the Coast
Guard using the Federal eRulemaking
Portal at https://www.regulations.gov.
See the ‘‘Public participation and
request for comments’’ portion of the
SUPPLEMENTARY INFORMATION section for
further instructions on submitting
comments.
A copy of the ICR is available through
the docket on the internet at https://
www.regulations.gov. Additionally,
copies are available from: Commandant
(CG–6P), ATTN: Paperwork Reduction
Act Manager, U.S. Coast Guard, 2703
Martin Luther King Jr. Ave. SE, STOP
7710, Washington, DC 20593–7710.
FOR FURTHER INFORMATION CONTACT: A.L.
Craig, Office of Privacy Management,
telephone 202–475–3528, or fax 202–
372–8405, for questions on these
documents.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
lotter on DSK11XQN23PROD with NOTICES1
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA L
Conflict SEP.
Date: March 29, 2022.
Time: 11:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Division of
Extramural Review, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: March 7, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–05137 Filed 3–10–22; 8:45 am]
VerDate Sep<11>2014
17:10 Mar 10, 2022
Jkt 256001
SUMMARY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NINDS Contract Review.
Date: April 4, 2022.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Marilyn Moore-Hoon,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Activities, National Institute of Neurological
Disorders and Stroke, 6001 Executive
Boulevard, Bethesda, MD 20892, 301–827–
9087, mooremar@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: March 7, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–05138 Filed 3–10–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2022–0155]
Information Collection Request to
Office of Management and Budget;
OMB Control Number: 1625–0122
AGENCY:
BILLING CODE 4140–01–P
PO 00000
Coast Guard, DHS.
Frm 00064
Fmt 4703
Sfmt 4703
Sixty-day notice requesting
comments.
SUPPLEMENTARY INFORMATION:
Public Participation and Request for
Comments
This notice relies on the authority of
the Paperwork Reduction Act of 1995;
44 U.S.C. 3501 et seq., chapter 35, as
amended. An ICR is an application to
OIRA seeking the approval, extension,
or renewal of a Coast Guard collection
of information (Collection). The ICR
contains information describing the
Collection’s purpose, the Collection’s
likely burden on the affected public, an
explanation of the necessity of the
Collection, and other important
information describing the Collection.
There is one ICR for each Collection.
The Coast Guard invites comments on
whether this ICR should be granted
based on the Collection being necessary
for the proper performance of
Departmental functions. In particular,
the Coast Guard would appreciate
comments addressing: (1) The practical
E:\FR\FM\11MRN1.SGM
11MRN1
Agencies
[Federal Register Volume 87, Number 48 (Friday, March 11, 2022)]
[Notices]
[Pages 14023-14024]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-05139]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Advancing Gender Inclusive Excellence (AGIE)--Coordinating
Center U54.
Date: April 8, 2022.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Shivani Sharma, Ph.D., Scientific Review
Officer, Center for Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, (240) 507-7661, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Initiative Research in Hematology.
Date: April 11, 2022.
Time: 2:00 p.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Larry Pinkus, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4132, MSC 7802, Bethesda, MD 20892, (301) 435-
1214, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Endocrinology, Metabolism, Nutrition and
Reproductive Sciences.
Date: April 14, 2022.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Baskaran Thyagarajan, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 800B, Bethesda, MD 20892, (301)
867-5309, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Virology.
Date: April 15, 2022.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Kumud Singh, Ph.D., Scientific Review Officer,
Center for Scientific Review, 6701 Rockledge Drive, Bethesa, MD
20892, (301) 761-7830, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
[[Page 14024]]
Dated: March 7, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-05139 Filed 3-10-22; 8:45 am]
BILLING CODE 4140-01-P